Exabis Library
Welcome to the e-CCO Library!
DOP69: Glycans as an actor in the microbiome-immune response crosstalk.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP69: Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP69: Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with ulcerative colitis: a sub-analysis of the Navigator Study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP70: Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP70: Crohn's Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP70: Crohn’s Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP70: Exosomes derived from human umbilical cord mesenchymal stem cells to attenuate colitis through repairing intestinal mucosal barrier
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP71: Effectiveness of dose escalation in Crohn’s Disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy - A multicenter international cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1